Both BRCA1 and CREBBP are tumor suppressor genes that are important for hematopoiesis. We have previously shown that mouse Brca1 is essential for hematopoietic stem cell (HSC) viability. In contrast to Brca1 deficiency, which results in pancytopenia, we report here that Crebbp deficiency results in myeloproliferation associated with an increase of splenic HSCs as well as a lethal systemic inflammatory disorder (LD50 = 86 days). To investigate the interaction of these two proteins in hematopoiesis, we generated double Crebbp/Brca1 knockout mice (DKOs). To our surprise, DKOs had accelerated bone marrow failure compared with Brca1-deficient mice and this was associated with an even shorter lifespan (LD50 = 88.5 versus 33 days). Furthermore, Crebbp or Brca1 heterozygosity influenced the hematopoietic phenotype associated with complete deficiency of Brca1 or Crebbp, respectively. We also observed lower BRCA1 protein levels in hematopoietic tissues when CREBBP is absent. Collectively, these data suggest Crebbp and Brca1 functionally interact to maintain normal hematopoiesis.
INTRODUCTION
BRCA1 and CREB-Binding protein (CREBBP or CBP) are tumor suppressor genes that are important in normal development. Homozygous germline mutations in either of these genes are embryonic lethal in humans and mice. In humans, heterozygous germline CREBBP mutations cause Rubenstein-Taybi Syndrome, a developmental disorder (short stature, intellectual disability, etc.) that includes a predisposition to leukemia (Miller and Rubinstein, 1995; Schorry et al., 2008) . Unlike CREBBP mutations, BRCA1 mutations do not predispose humans to hematopoietic neoplasia but do predispose to other solid tumors, such as pancreatic and prostate cancers, in addition to breast and ovarian cancers Miki et al., 1994) .
Mice haploinsufficient for Crebbp develop myeloproliferative disorders and myelodysplastic syndromes by 1 year of age, which can progress to full-blown malignancies . Complete deletion of Crebbp in hematopoietic stem cells (HSCs) impairs T and B cell development Xu et al., 2006) and increases differentiation to granulocytic and monocytic lineages . In addition, either mono-or biallelic loss of Crebbp in bone marrow is reported to impair the self-renewing capacity of HSCs .
Although BRCA1 mutations do not predispose mice to leukemia, mice conditionally deficient for Brca1 in embryonic HSCs develop a severe pancytopenia and die within 3 months of age . This is quite different from mice conditionally deficient for Brca1 in adult HSCs and progenitors using Mx1-Cre activation, which leads to a modest reduction in HSCs and mild bone marrow dysfunction (Vasanthakumar et al., 2016) .
Although Crebbp and Brca1 are both required to preserve normal HSC pools in bone marrow, their individual deficiencies result in distinct consequences Vasanthakumar et al., 2016; . To investigate functional interactions of Brca1 and Crebbp in hematopoiesis, we co-deleted both genes in HSCs and progenitors using the hematopoietic system-specific Vav1-iCre . Unexpectedly, we found that Crebbp-deficiency phenotypes are dependent on the presence or absence of Brca1. Crebbp deficiency in the background of normal Brca1 led to leukocytosis and neutrophilia, whereas co-deletion of Crebbp with Brca1 led to a more severe pancytopenia than that found for Brca1 deficiency alone. We also show that, in contrast to previous studies , hematopoietic loss of Crebbp alone resulted in a shift in the balance of HSCs where the decrease in the bone marrow was made up for in an increase in the spleen, rather than an overall shortage of HSCs. Furthermore, Crebbp heterozygosity showed enhanced hematopoietic defects in young mice with Brca1-deleted bone marrow, whereas Brca1 heterozygosity showed mild attenuation of pathogenic consequences in Crebbp-deficient mice. Further support for a functional interaction between BRCA1 and CREBBP was found where BRCA1 levels were altered in Crebbp-deficient thymus and bone marrow-derived macrophages (BMDMs), adding support that these two genes cooperate in vivo.
RESULTS

Deficiency of Crebbp in Mouse Hematopoietic Tissue Leads to an Inflammatory Disorder
We, and others, have discovered that deletion of Brca1 in HSCs results in either hematopoietic failure by 1 month of age when deleted in embryonic HSCs or a moderate reduction in bone marrow function when deleted in adult HSCs Vasanthakumar et al., 2016) . Crebbp has also been shown to contribute to maintenance of normal levels of early progenitors . Since Brca1 and Crebbp are important in hematopoiesis, we tested the functional interaction of these genes in knockout mice. Specifically, we conditionally deleted Crebbp alone or with Brca1 using the early hematopoietic system-specific Vav1-iCre and compared them with previously described Vav1-iCre;Brca1 F/F mice .
Vav1-iCre;Crebbp F/F mice survived a median 86 days ( Figure 1A ), and their mortality was associated with an unexpected severe skin phenotype ( Figure 1B ). This included skin flaking that began at 4-5 weeks of age with alopecia in the tail, eyelids, and ears. This progressed to widespread alopecia, flaking, and ulceration by 3-4 months of age. Once severe dermatitis developed, mice became moribund and were euthanized. Similar to age-matched controls ( Figure 1C ), skin from young pre-symptomatic Vav1-iCre;Crebbp F/F mice showed normal epidermal structure ( Figure 1D , left). However, higher magnification showed abnormal granulocyte infiltration (black arrows) in the dermal layers ( Figure 1D , right). Compared with normal skin structure in adult mice (Figure 1E) , diseased Vav1-iCre;Crebbp F/F adult mice showed significant epidermal hyper-proliferation and a fibrotic dermal layer ( Figure 1F , left) with granulocytes (black arrows) and mast cells (white arrow) ( Figure 1F , right). Unlike biallelic Crebbp-deficient mice, heterozygous Vav1-iCre;Crebbp F/+ mice showed long-term survival and did not have skin abnormalities during their lifespan (data not shown).
Young Vav1-iCre;Crebbp F/F mice also showed lung inflammation ( Figure 1H , left). Higher magnification (Figure 1H, right) showed localized plasma cell accumulations (hatched arrow) and pockets of foamy macrophages (white arrow) that accompanied granulocyte infiltration (black arrows). Immune cell infiltration persisted in lungs of older diseased Vav1-iCre;Crebbp F/F mice ( Figure 1J , left), with frequent Immunoglobulin-rich Russell bodies (orange arrows) in plasma cell-dense regions (hatched arrow) of the lungs ( Figure 1J , right). Representative WT lungs from young ( Figure 1G ) and adult ( Figure 1I ) mice are shown for comparison.
Similar to other Crebbp-deficiency studies , Vav1-iCre; Crebbp F/F mice developed splenomegaly ( Figure 2A ). Compared with controls Crebbp-deficient spleens were enlarged as early as 1 month of age (1.2% of body weight versus 0.5% body weight in control, p < 0.0001) (Figure 2A, left) and by adulthood (Figure 2A , right) had $6-fold greater spleen weight than littermate controls (2.7% of body weight in Crebbp-deficient mice compared with 0.5% in controls, p < 0.01). In contrast to splenomegaly, bone marrow cellularity in Vav1-iCre;Crebbp F/F mice was similar to controls ( Figure S1A ).
Compared with age-matched controls ( Figures 2B and 2C ), H&E stains from young and adult Vav1-iCre; Crebbp F/F mice ( Figures 2D and 2E ) showed age-related progression of extramedullary hematopoiesis in red pulp with concomitant depletion of lymphoid structure in white pulp.
In parallel with the inflammatory phenotype, Vav1-iCre;Crebbp F/F mice had leukocytosis. Elevated white blood cells (WBCs) ( Figure 2F ) were present in young Crebbp-deficient mice (4-8 weeks) and persisted throughout adulthood (8-24 weeks) (gray circles). The WBC differential showed Vav1-iCre;Crebbp F/F mice had neutrophilia, monocytosis, and eosinophilia, with neutrophils increasing with age ( Figures  2G-2I ). Lymphocyte counts were normal ( Figure 2J ). In contrast to the previous reports of Mx1-Cre-mediated deletion of Crebbp in adulthood , we did not observe thrombocytopenia in Va-v1-iCre;Crebbp F/F mice ( Figure S1B ). Both young and adult Crebbp-deficient mice were anemic ( Figures 2K-2M ).
HSC frequencies (CD150 + CD48 À Lineage -Sca-1 + ckit + ;CD150 + CD48 À LSK) (Kiel et al., 2005) in bone marrow from 4-to 8-week-old Vav1-iCre;Crebbp F/F mice were lower compared with age-matched littermate controls ( Figure 2N , left). Although this finding is consistent with previous reports , we also noted an increase in splenic HSCs ( Figure 2N , right). Both spleen and bone marrow from 4 to 8 week-old Crebbp-deficient mice showed higher levels of common myeloid progenitors (CMP, CD34 + CD16/32 low CD127 À Sca-1 À LK), myeloid granulocyte/monocyte mid progenitors (GMP; CD34 + CD16/32 high CD127 À Sca-1 À LK) (Akashi et al., 2000) , and granulocyte/monocyte late progenitors (Gr1 + Mac1 + ; CD11b + Gr1 + ) ( Figures 2O-2Q ), as well as CD3 + T cell progenitors ( Figure 2S ). In agreement with previous reports identifying a role for CREBBP in B cell maturation (Xu et al., 2006; , loss of Crebbp in bone marrow resulted in significantly reduced ProB/PreB-cell frequencies (CD43 -B220 hi /B220 lo ) in bone marrow ( Figure 2R , left) with less of an effect in spleen ( Figure 2R , right). The inverse changes in T and B cell progenitor frequencies in Crebbp-null mice may explain the lack of net changes in total lymphocyte counts ( Figure 2J ). Megakaryocyte/erythroid mid progenitors (MEPs; CD34 À CD16/32 low CD127 À Sca-1 À LK) (Akashi et al., 2000) were higher in Vav1-iCre;Crebbp F/F bone marrow and spleen, but only splenic late erythroid progenitors were higher ( Figures 2T and 2U ).
This is the first report of the use of the Vav-Cre allele to achieve biallelic deletion of Crebbp in adult and embryonic HSCs. These robust phenotypic data (inflammatory disorder, myeloproliferation) complement prior reports of Crebbp deficiency phenotypes. The other reports either studied heterozygous germline Crebbp knockouts or used the Mx1-Cre allele to achieve biallelic deletion of Crebbp in HSCs. For comparison of previous results to the data presented here, we have included a table comparing phenotypes (Table S1 ).
Brca1 and Crebbp Co-deficiency in Hematopoietic Tissue Leads to Increased Mortality due to Severe Bone Marrow Failure
To investigate the functional interaction of Brca1 and Crebbp genes in hematopoietic tissue, we deleted both genes in bone marrow and compared them with each of the single knockouts. To our surprise, Vav1-iCre;Brca1 F/F ;Crebbp F/F (double Crebbp/Brca1 knockout mice [DKO]) mice died much earlier (LD50 = 33 days) than Vav1-iCre;Crebbp F/F (LD50 = 86 days) or our previously published Vav1-iCre;Brca1 F/F mice (LD50 = 88.5 days) ( Figure 3A ; p < 0.001). The detrimental effect of Brca1/Crebbp co-deletion was also apparent in our ability to generate only eight DKO mice over 3 years, despite optimal breeding schemes. Crebbp loss in the DKO mice did not result in skin abnormalities, possibly because these mice did not survive to an age where severe skin phenotypes in Vav1-iCre;Crebbp F/F mice developed (3-4 months of age). Histology of bone marrow from the DKO mice showed decreased cellularity ( Figures 3B and 3C ). Bone marrow cell numbers were 80% lower in DKOs compared with control mice ( Figure 3D ). As expected, DKOs showed absence of bone marrow HSCs ( Figure 3E ) and loss of most mid and late progenitors ( Figure S2) . DKOs (open diamonds), like Vav1-iCre;Brca1 F/F (downward triangles), developed pancytopenia that was even a more severe than age-matched Vav1-iCre;Brca1 F/F mice ( Figures 3F-3L ). Together, these data show that Crebbp and Brca1 have distinct effects on hematopoiesis, where Crebbp restrains aberrant leukocytosis and possible HSC mobilization and also compensates for Brca1 loss to maintain HSCs/progenitors.
Brca1 and Crebbp Gene Dosage Impacts Hematopoiesis
Heterozygous CREBBP mutations in humans predispose patients with Rubenstein-Taybi Syndrome to hematopoietic neoplasia (Miller and Rubinstein, 1995; Schorry et al., 2008) . Also, Brca1 heterozygosity has been associated with increased frequency of febrile neutropenia after chemotherapy . Whether heterozygous mutations in either gene impact other phenotypes is not known. Here, we tested whether the heterozygous states of either Crebbp or Brca1 affected the deficient phenotypes of the other. Combined Brca1 and Crebbp heterozygosity (Vav1-iCre; Brca1 F/+ ;Crebbp F/+ ) did not affect survival ( Figure 4A , gray line) or CBCs ( Figures 4B-4F , open circles versus open squares), except for a mild but significant increase in monocytes ( Figure 4E ). Mice with Brca1 heterozygosity combined with complete Crebbp deficiency (Vav1-iCre; Brca1 F/+ ;Crebbp F/F ) showed slightly longer survival than Vav1-iCre;Crebbp F/F mice, but this change was not significant (LD50 = 107 versus 86 days, p = 0.069) ( Figure 4A , dotted versus solid line). However, young Vav1-iCre;Brca1 F/+ ;Crebbp F/F mice displayed lower WBC counts (p < 0.05) compared with Vav1-iCre;Crebbp F/F mice; individual counts for neutrophils (NE) (p = 0.073), monocytes (MO) (p = 0.06), and eosinophils (EO) (p = 0.094), although lower, were not significant ( Figures  4B-4E ; gray triangles versus gray circles). Brca1 heterozygosity in Crebbp-deficient mice led to a decrease of RBC counts ( Figure 4G , open circles versus gray triangles).
Brca1 haploinsufficiency in Vav1-iCre; Brca1 F/+ ;Crebbp F/F mice (gray triangles) normalized splenic HSCs compared with Crebbp-deficient mice ( Figure 4H , right; gray circles versus triangles) and attenuated most bone marrow myeloid progenitors. Except for late granulocyte/monocyte (Gr1 + Mac1 + ) progenitors spleen showed similar trends ( Figures 4I-4K ). In addition, Vav1-iCre;Brca1 F/+ ; Crebbp F/F splenic T cells were normalized toward wild-type (WT) frequencies (open circles) ( Figure 4L , right). Brca1 heterozygosity (gray triangles) did not significantly alter Crebbp-deficiency-associated ProB/PreB loss in bone marrow ( Figure 4M , left). Splenic early erythoid progenitors were unchanged ( Figure 4N ), whereas late erythroid progenitors were elevated in Vav1-iCre; Brca1 F/+ ;Crebbp F/F mice compared with controls ( Figure 4O , right), although RBCs were decreased with Brca1 heterozygosity ( Figure 4G ). We did observe a mild but insignificant reduction in lifetime incidence of skin abnormalities in Vav1-iCre; Brca1 F/+ ;Crebbp F/F compared with Vav1-iCre;Crebbp F/F mice ( Figure 4P ; p = 0.083, Fisher's exact test).
Hematopoietic abnormalities have been previously reported for Crebbp heterozygous mice that appear in late adulthood (>1 year) . We tested whether a heterozygous Crebbp genetic background affected young mice that were Brca1-deficient. Although Crebbp heterozygosity did not alter lifespan of Brca1-deficient mice ( Figure 4Q , Vav1-iCre;Brca1 F/F ;Crebbp F/+ ), WBC and neutrophil counts were moderately reduced ( Figures 4R and 4S ) and RBC counts trended lower ( Figure 4T ). That Crebbp and Brca1 allele dosage influence the deficiency phenotype of the other is further evidence these two genes cooperate. However, it is not clear whether this cooperation is direct or indirect.
BRCA1 Protein Is Altered in CREBBP-Deficient Hematopoietic Tissues
Since previous data have shown that CREBBP regulates BRCA1 gene expression (Ogiwara and Kohno, 2012; Pao et al., 2000) , we explored whether similar direct relationships were present in hematopoietic tissue. We chose thymus as our model hematopoietic tissue for two reasons: (1) thymus has robust mRNA (Gowen et al., 1996) and (2) it is a less heterogeneous, T cell-restricted tissue compared with bone marrow and spleen.
Consistent with the prior report of transcriptional regulation of BRCA1 by CREBBP (Ogiwara and Kohno, 2012) , Brca1 mRNA in the thymus of Vav-Cre;Crebbp F/F mice ( Figure 5A ) was lower compared with WT BRCA1. Similarly, we found that Vav-Cre;Crebbp F/F BRCA1 protein in thymus was decreased, but to a greater extent than mRNA ( Figures 5C and 5D ). The specific reactivity of the mouse BRCA1 antibody (Santa Cruz SC287.17) was established in WT thymus using fully humanized BRCA1 mouse thymus as a negative control ( Figure S3 ). Compared to WT, Crebbp deficiency in thymic tissue from Vav1-iCre;Crebbp F/F mice was confirmed by loss of mRNA ( Figure 5B ) and protein ( Figure 5E ). To evaluate heterogeneity of cell types in the thymus, we performed flow cytometry on Crebbp-deficient thymic tissue. The data were consistent with prior reports Xu et al., 2006) where Vav1-iCre;Crebbp F/F tissue showed a significant decrease in CD4+/CD8+ double-positive cell frequencies with a shift toward a higher frequency of CD4-/ CD8-double-negative and CD8+ single-positive cells compared with WT ( Figure S4 ). Because Brca1 expression may vary between CD4 and CD8 double-positive, single-positive, and double-negative T cells, it remains possible that differences in BRCA1 protein detected between WT and Vav1-iCre;-Crebbp F/F thymus arose from changes in T cell lineages with differing levels of BRCA1.
To address issues of cell-type heterogeneity present in intact hematopoietic tissue, we also compared Brca1 expression in primary bone marrow-derived macrophages (BMDMs) from WT and Vav1-iCre; Crebbp F/F mice. qPCR showed that WT and Vav1-iCre;Crebbp F/F differentiated BMDM cultures had similar expression levels of macrophage and dendritic cell markers F4/80 and CD11c, respectively, and suggests relative homogeneity between these two genotypes ( Figures S5A and S5B , respectively). Brca1 mRNA was not significantly different in the knockout and WT BMDMs ( Figure 5F ), whereas BRCA1 protein from Crebbp-deficient BMDMs was lower than in controls ( Figures 5H and 5I ). Compared to WT, Crebbp deficiency in BMDMs from Vav1-iCre;Crebbp F/F mice was confirmed by loss of mRNA ( Figure 5G ) and protein ( Figure 5J ). To address whether reduced levels of BRCA1 in Crebbp-deficient BMDMs were indirectly associated with altered proliferation rates compared with WT, we performed propidium iodide stain cell cycle analysis and found both genotypes to have similar fraction of cells in G1, G2, and S phase ( Figure S5C ). This is the first report of BRCA1 detection in macrophages and suggests that BRCA1 protein changes in Crebbp-deficient BMDMs are independent of proliferation rates and that CREBBP regulates BRCA1 using a post-transcriptional mechanism in BMDMs.
DISCUSSION
We show that mice deficient of Crebbp in the bone marrow present with a previously undescribed lethal systemic immune disorder that manifests as a fully penetrant, severe dermatitis and alopecia. This is consistent with a previous study that showed that a T-reg-specific double knockout of Crebbp and its paralog, p300, results in an early-onset lethal autoimmune disease that includes dermatitis . In the latter study, absence of Crebbp alone in T-reg cells did not result in severe autoimmunity, which suggests that systemic inflammatory disease in the Vav1-iCre;Crebbp F/F mice herein involves Crebbp deficiency in a broader set of immune cell types. It is clear from our studies, as well as earlier reports , that Crebbp deficiency disrupts T cell homeostasis beyond T-reg function as shown with increase in CD8 single-positive cells in thymus. Whether this translates to elevation in CD8-positive autoreactive and effector T-cells to mediate full-blown skin disease needs further investigation. A role for neutrophils in autoimmune disease has been reported (Nemeth and Mocsai, 2012) . Therefore, presence of granulocytes in the dermal layers prior to skin abnormalities may potentiate later phases of autoimmune processes. Finally, it is also possible that Crebbp-deficient mice display impaired wound healing responses in the event that hematopoietic loss of Crebbp disrupts M2 macrophages differentiation or function.
Crebbp deficiency also led to a much earlier and more severe myeloproliferative phenotype compared with previous reports in older haploinsufficient mice . This further confirms the importance of Crebbp in hematopoiesis and supports earlier studies that show that Crebbp acts as a key immune modulator of inflammatory cell activity and differentiation in the bone marrow Lennard Richard et al., 2016; Liu et al., 2013 . Our data suggest that loss of Crebbp results in HSC mobilization, evidenced by HSC population balance shifting from bone marrow to spleen, as well as a consistent granulocytosis. The neutrophilia and monocytosis was a fully penetrant phenotype present before full-blown skin disease, suggesting that leukocytosis in Crebbp-deficient mice is an inherent, rather than acquired (e.g., infection), condition. Therefore, it is attractive to speculate that Crebbp is required to prevent inappropriate HSC mobilization and that modulating Crebbp may be a mechanism to regulate hematopoiesis and innate immune responses.
The abundance of splenic HSCs in our Crebbp-deficient mice show that Crebbp is not required to maintain an adequate pool of HSCs per se. This differs from previous reports that Crebbp displays cell autonomous and non-autonomous haploinsufficiency in bone marrow to maintain functional self-renewing HSCs . These conclusions were based on reduced secondary transplant efficiency associated with lower LSK CD34-populations in the bone marrow of Crebbp heterozygous mice. Similarly, a later study showed that deletion of Crebbp in adult HSC also resulted in a lower reconstitution capacity as (I) and (J) show densitometric analysis of BMDM western blot data. Thymus Brca1 mRNA was measured in WT (n = 10) and Vav1-iCre; Crebbp F/F (n = 5) mice. Thymic BRCA1 protein was measured in WT (n = 6) and Vav1-iCre; Crebbp F/F (n = 6) mice. BMDM Brca1 mRNA was measured in WT (n = 5) and Vav1-iCre; Crebbp F/F (n = 5) mice. BMDM BRCA1 protein was measured in WT (n = 4) and Vav1-iCre;Crebbp F/F mice (n = 5). Values represent means G SEM. Statistical significance was assessed using a two-tailed Student's t test (***p < 0.001, ****p < 0.0001).
well as decreased frequency of LSK CD34 -Flt3cells that was independent of mobilization to the spleen . A possible reason for the discrepancy between our and earlier splenic HSC quantification is that we confine our estimation to the LSK CD150 + CD48 - (Kiel et al., 2005) population that is more enriched for self-renewing HSCs, rather than multipotent and early progenitors, used in earlier studies.
Owing to the mixed background of our mice in this study, we were unable to address the transplant repopulation capacity of Crebbp-deficient HSCs.
We show that co-deletion of tumor suppressors Crebbp and Brca1 in bone marrow results in shortened lifespan compared with the already reduced survival of single knockouts. The advanced pancytopenia in DKOs highlights an ability of Crebbp to compensate for Brca1 at an early stage of hematopoiesis. BRCA1 deficiency in cells is often associated with DNA damage-induced apoptosis that arises from defects in multiple pathways of DNA repair, including nuclear excision repair (Hartman and Ford, 2002) , transcription-coupled repair of oxidative DNA damage (Abbott et al., 1999) , homologous recombinational repair (Moynahan et al., 1999; Snouwaert et al., 1999) , and non-homologous end-joining (Baldeyron et al., 2002; Zhong et al., 2002a Zhong et al., , 2002b . Since Crebbp has recently been shown to maintain genomic integrity during lineage specification of hematopoietic cells (Horton et al., 2017) , CREBBP may partially compensate for defective DNA repair in Brca1-deficient HSCs and progenitors. We hypothesize that combined deletion of Brca1 and Crebbp results in more severe global DNA damage than with Brca1 and Crebbp single knockouts and that accelerated accumulation of genomic abnormalities leads to accelerated cell death rather than transformation. We therefore hypothesize that complete inhibition or loss of both tumor suppressors in blood cancers may be synthetic lethal, and if it is, this concept could be exploited to develop therapeutic targets of each in either Brca1or Crebbp-deficient cancers.
Finally, we show that BRCA1 protein is altered in Crebbp-deficient hematopoietic tissue. In thymus, decreased BRCA1 protein in Crebbp-deficient thymus correlates with decreased Brca1 mRNA, which is consistent with prior reports that Brca1 is under transcriptional regulation by Crebbp (Ogiwara and Kohno, 2012) . In contrast, Crebbp-deficient BMDMs have decreased BRCA1 protein with no significant decrease in Brca1 mRNA, suggesting the possibility of post-transcriptional regulation of BRCA1 protein by CREBBP.
Although our data show that BRCA1 levels are decreased in CREBBP-deficient hematopoietic tissue, our in vivo data do not support a simplistic hypothesis that Crebbp-deficient phenotypes arise owing to loss of BRCA1 protein. It is interesting to speculate that reduced leukocytosis with Brca1 heterozygosity in Crebbp-deficient mice ( Figures 4B-4D ) may reflect a reduction of BRCA1 protein below haploinsufficient levels that occurs in WT mice.
The compensatory roles for Brca1 and Crebbp will lead us to further investigate how these tumor suppressor genes cooperate in developmental systems and how heterozygosity of pathogenic mutations in each gene contributes to tumorigenesis that results from the loss of the other.
Limitations of the Study
Key limitations of this study relate to the poor health of Crebbp/Brca1 DKO mice. The number of surviving DKO mice was low, and this limited statistical power for more in depth in vivo analyses. For example, since hematopoietic tissue was depleted we could not expand primary cells in culture or perform extensive biochemical analyses. Inducible systems will circumvent early lethality and allow for the comparison of the acute effects of co-deleting both genes in vivo as well as in culture. Another significant limitation was our inability to assess HSC self-renewal capacities with transplantation experiments as the Crebbp allele was obtained from a mixed background.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.08.031.
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We thank members of the Ross lab for their intellectual contributions to this work. This work was supported by NIH R01 HL132251-02, the Nancy Tartaglino Richards Cancer Genetics Research Fund, the Lucy and Figure S1 . Crebpp deficiency in bone marrow does not result in thrombocytopenia (Related Figure  A) No difference in bone marrow cellularity between control (WT) and F/F mice. B) Platelets were not different between WT (Vav1-iCre negative, open circles) and Vav1-iCre;Crebbp F/F mice (grey circles) at young (4-8 weeks) or adult (>8-24 weeks) age. Numbers are the same as in Figure 2 for other CBC parameters. Values represent mean ±SEM. Statistical significance was assessed using a twotailed Student's t test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Crebbp is necessary for HSC selfrenewal. Number of functional HSCs (LSK CD34-) was lower in >9 months mice and have reduced self-renewal capacity during serial transplantation.
Crebbp is not required to maintain an adequate pool of HSCs per se. Reduced BM HSC frequencies (CD150+CD48-Lineage-Sca-1+ckit+;CD150+CD48-LSK) was seen in 4-8 week old mice, with increased SP HSC frequencies suggesting HSC mobilization or extramedullary hematopoiesis (EMH). The discrepancy with previous reports may be because this HSC population is highly enriched for self-renewing HSCs, rather than multipotent and early progenitors (Kiel et al., 2005) . Due to the mixed background of our mice in this study, we were unable to address the transplant repopulation capacity of Crebbpdeficient HSCs.
germline Heterozygous deletion Crebbp+/ 9-12 old mice showed decreased long-term HSCs (LSK CD34-).
MX1-cre biallelic deletion Ablation of Crebbp in hematopoietic tissues of adult mice reduced BM HSC (LSK CD34-Flt3-) frequencies, with no change in spleen HSC frequencies. Reduction of HSCenriched population led to exhaustion of HSCs upon serial transplantation and replicative stress.
Myeloproliferation germline
Heterozygous deletion Crebbp is important for maintaining normal levels of early progenitors of the myeloid lineage. Increased myeloid (Mac1+Gr+) and erythroid (TER119+) progenitors in the spleen in old (>12 months) mice with splenomegaly. These mice also showed decreased BM cellularity and modest but significant decreases in BM hematopoietic cell types and significant increase in myeloid cells in PB. No changes in BM cellularity observed at 8 weeks of age. MX1-cre biallelic deletion Peripheral myeloid cells trended to increase at 4-weeks post pIpC treatment (6-10 week old mice were treated with pIpC for 10 days) and show a significant increase at 28 weeks. Increase in myelpoid progenitor to LSK CD34-Flt3-ratio. (Xu et al., 2006) Impaired B-cell maturation. Loss of Crebbp at Pro-B cell stage lead to moderate decreases in B-cell number in PB and SP, with no changes in Tcell number. Although no significant alteration in ProB and PreB ratios were seen in BM, there was a decrease in mature B cells.
No change in lymphocyte counts in PB. Increased CD3+ T-cell progenitors in BM and SP. Reduced ProB/PreB-cell frequencies (CD43-B220hi/B220lo) in BM with less of an effect in spleen. In thymus significant decrease in CD4+/CD8+ double positive cell frequencies with a shift toward a higher frequency of CD4-/CD8double negative and CD8+ single positive cells compared to WT.
germline Heterozygous deletion Impaired B-cell maturation. When WT BM were transplanted into lethally irradiated Crebbp+/-mice, the frequency of BM B-cells (B220+) was found to be decreased 5 months after transplantation.
Lck-Cre biallelic deletion Deletion of Crebbp in CD4-/CD8double negative thymocytes leads to defective B-and T-cell development in adult mice, specifically a decrease in CD4+/CD8+ double positive thymocytes and an increase in CD8+ single positive thymocytes.
germline Heterozygous deletion Reduced B cell counts in PB and modest but significant decrease in colony forming capacity of pre-B and myeloid progenitors. Reduced B and T progenitors in BM. Some B and T cell abnormalities were apparent by 3 months of age.
Inflammatory disorder
Foxp3-cre biallelic deletion Double knockout of Crebbp and its paralog p300 in T-reg cells results in an early-onset lethal autoimmune disease that includes dermatitis. Absence of Crebbp alone in T-reg cells did not result in autoimmunity.
Lethal systemic immune disorder and associated severe dermatitis and alopecia seen by 4-5 weeks of age. Hematologic neoplasias with advanced age; of Crebbp+/-mice between 10 and 21 months of age, 39% either developed hematologic neoplasia with leukemia and tumors of hematopoietic origin or harbored tumorigenic cells. Due to the sever skin phenotype, Vav1-iCre;Crebbp F/F mice had to be terminated at a young age (median survival 86 days). Neither Vav1-iCre;Crebbp F/F nor Vav1-iCre;Crebbp F/+ mice developed leukemias or other hematological neoplasias by 4-8 weeks of age.
CD19-cre biallelic deletion (Xu et al., 2006) Loss of Crebbp at Pro-B cell stage does not result in B-cell lymphomas, although there was increased death due to unknown causes after 1 year of age.
germline Heterozygous deletion Adult Crebbp+/-mice or WT mice transplanted with Crebbp+/-BM develop myelodysplasia, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS).
germline Heterozygous deletion Adult Crebbp+/-mice (9-12 months) develop dysplastic features.
Thrombocytopenia MX1-cre biallelic deletion Thrombocytopenia was seen in adulthood.
No thrombocytopenia was seen in young (4-12 week) or adult (8-24 weeks) mice.
